Last updated: February 19, 2026
Canadian patent CA2869945, titled "Compositions and Methods for Treating Disorders Associated with Protein Aggregation," was filed on October 14, 2014, and granted on October 23, 2018. The patent's assignee is Amgen Inc. This analysis details the patent's core claims, its asserted scope, and its position within the broader drug patent landscape relevant to protein aggregation disorders.
What is the Core Invention of CA2869945?
The patent protects novel compositions and methods for treating disorders characterized by the aggregation of specific proteins. The primary target identified within the patent is the aggregation of amyloid beta (Aβ) peptides, a hallmark of Alzheimer's disease. The invention centers on a class of small molecules designed to inhibit the formation of these aggregates.
What Specific Mechanisms Does the Patent Address?
CA2869945 discloses compounds that function as inhibitors of amyloid beta aggregation. The core mechanism involves the interaction of these small molecules with amyloid beta peptides to prevent their misfolding and subsequent formation of amyloid fibrils and plaques.
The patent details the chemical structures of these inhibitory compounds. These are small organic molecules, distinct from larger biological therapeutics like antibodies. Their mode of action is described as interfering with the self-assembly process of amyloid beta monomers into oligomers and fibrils.
What are the Key Claims of CA2869945?
The patent contains multiple claims, defining the scope of protection. The most significant claims are directed towards the chemical entities themselves and their use in treating specific conditions.
Independent Claims:
- Claim 1: This is a foundational claim defining a compound of Formula I or a pharmaceutically acceptable salt thereof. Formula I encompasses a specific chemical structure with defined substituent groups. The core structure and the variations allowed by the substituents define the patented chemical space. The formula includes a heterocyclic core, attached to various aromatic and aliphatic groups, with specific functional groups at defined positions.
- Claim 14: This claim pertains to a pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient. This claim extends protection to formulated versions of the active pharmaceutical ingredient.
- Claim 15: This claim covers a method of treating a disorder associated with protein aggregation, particularly amyloid beta aggregation, in a subject. The method involves administering to the subject an effective amount of a compound according to Claim 1 or a pharmaceutical composition according to Claim 14.
Dependent Claims:
Numerous dependent claims further refine the scope of the independent claims by:
- Specifying particular preferred embodiments of Formula I, narrowing down the range of substituents or preferred ranges for certain variables.
- Defining specific salts of the compounds.
- Detailing particular pharmaceutical compositions, such as those formulated for oral administration or specific dosages.
- Elaborating on the methods of treatment, specifying the type of disorder (e.g., Alzheimer's disease, mild cognitive impairment) or the patient population.
The breadth of Claim 1 is critical, as it defines the chemical entities for which protection is sought. The subsequent claims build upon this, extending protection to the formulated drug product and its therapeutic applications.
What is the Asserted Scope of Protection?
The asserted scope of CA2869945 extends to a specific class of small molecule inhibitors designed to prevent the aggregation of amyloid beta proteins. This includes:
- Novel Chemical Entities: The patent protects specific chemical structures, as defined by Formula I and its defined substituents. This provides Amgen with exclusive rights to manufacture, use, and sell these particular compounds.
- Pharmaceutical Formulations: Protection is granted to pharmaceutical compositions containing these active compounds, allowing for control over how the drug is delivered to patients.
- Therapeutic Methods: The patent claims the method of using these compounds to treat disorders characterized by protein aggregation, particularly those involving amyloid beta. This covers the application of the drug in a medical context.
The patent's focus on small molecules distinguishes it from other therapeutic approaches targeting protein aggregation, such as monoclonal antibodies that bind to and clear existing aggregates or pathological forms of the protein.
What is the Patent Landscape for Protein Aggregation Inhibitors?
The patent landscape for drugs targeting protein aggregation disorders, especially those related to amyloid beta, is highly competitive and crowded. Multiple therapeutic modalities and distinct chemical approaches are being pursued by various pharmaceutical companies.
Key Therapeutic Areas and Protein Targets:
- Alzheimer's Disease: This is a primary focus, with amyloid beta and tau proteins being the most heavily targeted. Patents in this area often cover:
- Antibodies against amyloid beta (e.g., aducanumab, lecanemab).
- Antibodies against tau.
- Small molecule inhibitors of beta-secretase (BACE1) and gamma-secretase, enzymes involved in amyloid precursor protein processing.
- Small molecules that modulate tau pathology.
- Compounds designed to prevent amyloid beta aggregation, as seen with CA2869945.
- Parkinson's Disease: Targets include alpha-synuclein aggregation.
- Amyotrophic Lateral Sclerosis (ALS): Targets include TDP-43 and SOD1 aggregation.
- Huntington's Disease: Targets include huntingtin protein aggregation.
Competitive Landscape for Amyloid Beta Aggregation Inhibitors:
Within the specific domain of amyloid beta aggregation inhibition, several companies and research institutions hold patents on various classes of compounds and therapeutic strategies.
- Small Molecule Inhibitors: CA2869945 falls into this category. Other patents in this space might cover different chemical scaffolds or mechanisms, such as compounds that prevent fibril elongation or promote fibril disaggregation.
- Antibody Therapeutics: A significant portion of recent innovation and market activity for Alzheimer's disease has been in monoclonal antibodies designed to clear amyloid beta plaques. Companies like Biogen, Eisai, Eli Lilly, and Roche have extensive patent portfolios in this area. Patents typically cover specific antibody sequences, epitopes targeted, and methods of use.
- Enzyme Inhibitors: Patents for BACE1 and gamma-secretase inhibitors were numerous in the past, although many candidates faced clinical trial failures.
Patent Strategy Considerations:
- Freedom to Operate (FTO): Companies developing new small molecule inhibitors for protein aggregation disorders must conduct thorough FTO analyses to ensure their compounds do not infringe existing patents, including those like CA2869945. This involves mapping the chemical space of their invention against the claims of prior art patents.
- Patent Exclusivity: The duration of patent protection is critical for recouping R&D investment. CA2869945, granted in 2018, will have an expiry date in 2034 (20 years from filing date), assuming no extensions. This provides a limited window for commercialization.
- Patent Thinness: In a crowded field, patent portfolios may be considered "thin" if they cover narrow chemical structures or have limited claims. CA2869945's strength lies in its defined chemical genus, but the efficacy and safety of compounds within this genus would be critical for market success.
- Evergreening: Companies may seek to extend patent life through new formulations, new indications, or new salts, which can create additional layers of intellectual property protection around a core drug.
Potential Overlap and Infringement:
Given the common target (amyloid beta aggregation) and similar therapeutic goal, there is a potential for overlap between the claims of CA2869945 and patents covering other small molecule inhibitors or even certain aspects of antibody binding if the antibodies interfere with the aggregation process through mechanisms that could be construed as related.
Companies developing compounds that modulate amyloid beta aggregation, particularly through small molecule mechanisms that inhibit aggregate formation, need to carefully scrutinize their IP to avoid direct infringement of Formula I or related dependent claims. The specific structure of the proprietary compound will determine the level of risk.
Key Takeaways
- Canadian patent CA2869945 protects a class of small molecules designed to inhibit amyloid beta aggregation, a key pathological feature of Alzheimer's disease.
- The patent's core protection lies in its claims covering specific chemical structures (Formula I), pharmaceutical compositions, and methods of treating protein aggregation disorders.
- The asserted scope is focused on small molecule intervention, distinct from antibody-based therapies that clear existing aggregates.
- The patent landscape for protein aggregation inhibitors, particularly for Alzheimer's disease, is highly competitive, with numerous patents covering antibodies, enzyme inhibitors, and various small molecule approaches.
- Companies developing similar therapeutics must conduct rigorous freedom-to-operate analyses to avoid infringing claims of patents like CA2869945.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds claimed in CA2869945?
The primary therapeutic target is the inhibition of amyloid beta (Aβ) aggregation, a key pathological process in Alzheimer's disease.
-
Does CA2869945 cover antibody-based therapies for Alzheimer's disease?
No, CA2869945 specifically claims small organic molecules and their use, not antibody-based therapies.
-
When does Canadian patent CA2869945 expire?
The patent was granted in 2018 and has a term of 20 years from its filing date of October 14, 2014, meaning it will expire on October 14, 2034, barring any extensions.
-
What is the difference between the claims for the compound and the pharmaceutical composition?
The claim for the compound protects the active chemical entity itself, while the claim for the pharmaceutical composition protects the drug when it is formulated with carriers, diluents, or excipients for administration to a patient.
-
Are there other patents protecting similar small molecule inhibitors of amyloid beta aggregation?
Yes, the landscape for small molecule inhibitors of amyloid beta aggregation is active, with multiple companies and research institutions holding patents on different chemical scaffolds and mechanisms of action aimed at this target.
Citations
[1] Amgen Inc. (2018). Compositions and Methods for Treating Disorders Associated with Protein Aggregation. Canadian Patent CA2869945. Filed October 14, 2014, Granted October 23, 2018.
